Skip to main content
A Family of four playing outdoors in the grass and sunshine)

Access and Health Security

Access to Our Products

Our products provide substantial and meaningful value to patients, healthcare providers, health insurance payers and healthcare systems around the world.

We are proud of these contributions and seek to ensure that patients and communities have access to a reliable supply of biopharmaceuticals and vaccines.


We work with governments, health insurance payers and other stakeholders to support timely and appropriate market entry and access, in order to enable appropriate patients to benefit from our therapies as quickly as possible. We value an ongoing dialogue with policymakers, advocacy groups and other stakeholders to understand and respond to their needs and expectations.

We articulate and communicate comprehensive evidence on the value of our innovations to inform access and reimbursement decisions, and we provide patient assistance programs and support advocacy efforts that improve access to care and affordability.

We are also committed to pricing practices that reflect the value our products bring to patients and society. To that end, we evaluate real-world and clinical trial data that demonstrate the clinical benefits our therapies deliver, as well as the cost they provide to overall healthcare. We also consider patient needs and preferences and how our therapies improve patients’ quality of life and productivity.

Health Security


A measure of the trust we have built is our position as a global leader in influenza pandemic preparedness and response. Thirty governments around the world rely on CSL Seqirus for pandemic influenza preparedness, including the US, the UK and Australia. CSL Seqirus also provides pandemic response commitments to the World Health Organization.

Our government partners reserve pandemic vaccine doses from our facilities to protect their populations in the event of an influenza pandemic. CSL Seqirus also supplies pre-pandemic vaccine stockpiles that could be deployed to first responders upon a declaration of an influenza pandemic.

CSL Seqirus has three state-of-the-art manufacturing facilities on three different continents, together with a global fill and finish network located close to our end markets.

In February 2022, CSL Seqirus renewed a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).